SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: dalroi who wrote (239)5/1/2002 7:35:10 AM
From: rkrw  Read Replies (2) of 508
 
Stefaan,
I agree with you 100%. I was teasing. And further, this is an indication expansion to an already approved drug, with long accumulated safety data. The only way I see the trial not showing stat significance is if the prednisone arm shows much more durability/less progression than expected and actimmune performs worse than assumed, which still should be much better than pbo/pred.

itmn also has a built in buffer to the trial in that the trial will continue blinded post data collection in Aug. So a strong trend toward significance could mean statistical significance a few months later. Only problem I see with this may be keeping people, since A is much more accessible off label than a year ago when most enrolled.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News